{"id":391694,"date":"2020-12-02T08:35:37","date_gmt":"2020-12-02T13:35:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=391694"},"modified":"2020-12-02T08:35:37","modified_gmt":"2020-12-02T13:35:37","slug":"silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/","title":{"rendered":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease<\/b><\/p>\n<p class=\"bwalignc\"><b><i>Collaboration with the University of Maastricht of the Netherlands<\/i><\/b><\/p>\n<p>TEANECK, N.J.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson\u2019s disease and to understand its mechanism of action.\n<\/p>\n<p>\nDr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve as Investigator Sponsor for the Phase 2B study. Dr. Kuypers&#8217; main topics of interest are MDMA and psychedelics and their effects on (social) cognition, creativity, hormones, and underlying brain mechanisms.\n<\/p>\n<p>\n\u201cThe signing of this clinical study agreement represents a significant milestone for the Company as we continue our work to bring novel therapeutics to patients in need,\u201d stated Eric Weisblum, Chairman and CEO of Silo Pharma. \u201cDr. Kuypers is one of the world\u2019s foremost clinical investigators in the field of psychedelics and has previously evaluated the concept of micro-dosing in her research.\u201d\n<\/p>\n<p>\nThe Phase 2B study is a human study to be conducted on a sufficient number of patients, the primary purpose of which is to evaluate the safety and efficacy of psilocybin and LSD on patients suffering from Parkinson\u2019s disease. The primary objective of this trial is to investigate the effects of repeated low doses of psilocybin and LSD on well-being and affect (self-rated), emotional and cognitive attention (computer tasks), and biological markers of neuroplasticity. Secondary objectives are to investigate the effects of repeated low doses of psilocybin and LSD on cognitive performance measures of memory and executive functioning, known to be impaired in Parkinson\u2019s disease (computer tasks) and emotion regulation Parkinson\u2019s symptoms, and biological markers of well-being (immune system, cortisol).\n<\/p>\n<p>\n\u201cParkinson\u2019s disease is a progressive nervous system disorder that affects 7-10 million people globally and currently has no cure,\u201d added Mr. Weisblum. \u201cOur goal, in collaborating with Maastricht University and Dr. Kuypers, is to bring hope to those suffering with this terrible disease. We expect to share additional information regarding protocol, ethics submission and initiation of the study as the information becomes available.\u201d\n<\/p>\n<p><b>About Silo Pharma <\/b><\/p>\n<p>\nSilo Pharma, Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.silopharma.com&amp;esheet=52340862&amp;newsitemid=20201202005179&amp;lan=en-US&amp;anchor=www.silopharma.com&amp;index=1&amp;md5=99cad10a34ed41e1bd0559f44f8d61f5\">www.silopharma.com<\/a>.\n<\/p>\n<p><b>Safe Harbor and Forward-Looking Statements<\/b><\/p>\n<p>\nThis news release contains &#8220;forward-looking statements&#8221; within the meaning of the \u201csafe-harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words \u201ccould,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201ccontinue,\u201d \u201cpredict,\u201d \u201cpotential\u201d and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201202005179\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201202005179\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">Investor Relations Contact<\/span>:<br \/>\n<\/b><br \/><b>Hayden IR<br \/>\n<\/b><br \/>Brett Maas<br \/>\n<br \/>646-536-7331<br \/>\n<br \/>Email: <a rel=\"nofollow\" href=\"mailto:brett@haydenir.com\">brett@haydenir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Netherlands Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Mental Health Health Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease Collaboration with the University of Maastricht of the Netherlands TEANECK, N.J.&#8211;(BUSINESS WIRE)&#8211; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson\u2019s disease and to understand its mechanism of action. Dr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-391694","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease Collaboration with the University of Maastricht of the Netherlands TEANECK, N.J.&#8211;(BUSINESS WIRE)&#8211; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson\u2019s disease and to understand its mechanism of action. Dr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve &hellip; Continue reading &quot;Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-02T13:35:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease\",\"datePublished\":\"2020-12-02T13:35:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/\"},\"wordCount\":753,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/\",\"name\":\"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-02T13:35:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk","og_description":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease Collaboration with the University of Maastricht of the Netherlands TEANECK, N.J.&#8211;(BUSINESS WIRE)&#8211; Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson\u2019s disease and to understand its mechanism of action. Dr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve &hellip; Continue reading \"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-02T13:35:37+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease","datePublished":"2020-12-02T13:35:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/"},"wordCount":753,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/","name":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-02T13:35:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201202005179r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-plans-for-a-phase-2b-investigator-lead-study-using-psychedelics-psilocybin-and-lysergic-acid-diethylamide-lsd-to-treat-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (\u201cLSD\u201d) to Treat Parkinson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=391694"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/391694\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=391694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=391694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=391694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}